Deferoxamine-conjugated AgInS<inf>2</inf>nanoparticles as new nanodrug for synergistic therapy for hepatocellular carcinoma

© 2017 Elsevier B.V. Herein, a new nanodrug that exhibits multi-therapeutic modalities for synergistic treatment of hepatocellular carcinoma is reported. The nanodrug is composed of carboxymethyl cellulose modified silver indium sulfide nanoparticle (CMC-AgInS2NP, served as a source of reactive oxyg...

Full description

Saved in:
Bibliographic Details
Main Authors: Isara Phiwchai, Titipun Thongtem, Somchai Thongtem, Chalermchai Pilapong
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85016618569&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/57864
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-57864
record_format dspace
spelling th-cmuir.6653943832-578642018-09-05T03:51:46Z Deferoxamine-conjugated AgInS<inf>2</inf>nanoparticles as new nanodrug for synergistic therapy for hepatocellular carcinoma Isara Phiwchai Titipun Thongtem Somchai Thongtem Chalermchai Pilapong Pharmacology, Toxicology and Pharmaceutics © 2017 Elsevier B.V. Herein, a new nanodrug that exhibits multi-therapeutic modalities for synergistic treatment of hepatocellular carcinoma is reported. The nanodrug is composed of carboxymethyl cellulose modified silver indium sulfide nanoparticle (CMC-AgInS2NP, served as a source of reactive oxygen species) covalently linked with deferoxamine (DFO, served as iron chelating agent). The DFO/CMC-AgInS2nanodrug was taken up by the HepG2 cell and accumulated within the cytosol as well as the nucleus, leading to induction of cell arrest in the G2/M phase and subsequent apoptosis cell death. Compared to DFO, the DFO/CMC-AgInS2nanodrug demonstrated better anti-proliferative activity against the HepG2 cell. As they were cultured in a medium supplemented with ferric ions, the HepG2 cells were induced to grow faster as compared to the cells without the addition of ferric ions. Fortunately, our nanodrug was found to inhibit the cell growth induced by ferric ions. Our results indicate that the nanodrug has synergistic effect for treatment of HepG2 cells via the intrinsic therapeutic property of CMC-AgInS2NP and the iron chelating capability of DFO. 2018-09-05T03:51:46Z 2018-09-05T03:51:46Z 2017-05-30 Journal 18733476 03785173 2-s2.0-85016618569 10.1016/j.ijpharm.2017.03.058 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85016618569&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/57864
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Pharmacology, Toxicology and Pharmaceutics
spellingShingle Pharmacology, Toxicology and Pharmaceutics
Isara Phiwchai
Titipun Thongtem
Somchai Thongtem
Chalermchai Pilapong
Deferoxamine-conjugated AgInS<inf>2</inf>nanoparticles as new nanodrug for synergistic therapy for hepatocellular carcinoma
description © 2017 Elsevier B.V. Herein, a new nanodrug that exhibits multi-therapeutic modalities for synergistic treatment of hepatocellular carcinoma is reported. The nanodrug is composed of carboxymethyl cellulose modified silver indium sulfide nanoparticle (CMC-AgInS2NP, served as a source of reactive oxygen species) covalently linked with deferoxamine (DFO, served as iron chelating agent). The DFO/CMC-AgInS2nanodrug was taken up by the HepG2 cell and accumulated within the cytosol as well as the nucleus, leading to induction of cell arrest in the G2/M phase and subsequent apoptosis cell death. Compared to DFO, the DFO/CMC-AgInS2nanodrug demonstrated better anti-proliferative activity against the HepG2 cell. As they were cultured in a medium supplemented with ferric ions, the HepG2 cells were induced to grow faster as compared to the cells without the addition of ferric ions. Fortunately, our nanodrug was found to inhibit the cell growth induced by ferric ions. Our results indicate that the nanodrug has synergistic effect for treatment of HepG2 cells via the intrinsic therapeutic property of CMC-AgInS2NP and the iron chelating capability of DFO.
format Journal
author Isara Phiwchai
Titipun Thongtem
Somchai Thongtem
Chalermchai Pilapong
author_facet Isara Phiwchai
Titipun Thongtem
Somchai Thongtem
Chalermchai Pilapong
author_sort Isara Phiwchai
title Deferoxamine-conjugated AgInS<inf>2</inf>nanoparticles as new nanodrug for synergistic therapy for hepatocellular carcinoma
title_short Deferoxamine-conjugated AgInS<inf>2</inf>nanoparticles as new nanodrug for synergistic therapy for hepatocellular carcinoma
title_full Deferoxamine-conjugated AgInS<inf>2</inf>nanoparticles as new nanodrug for synergistic therapy for hepatocellular carcinoma
title_fullStr Deferoxamine-conjugated AgInS<inf>2</inf>nanoparticles as new nanodrug for synergistic therapy for hepatocellular carcinoma
title_full_unstemmed Deferoxamine-conjugated AgInS<inf>2</inf>nanoparticles as new nanodrug for synergistic therapy for hepatocellular carcinoma
title_sort deferoxamine-conjugated agins<inf>2</inf>nanoparticles as new nanodrug for synergistic therapy for hepatocellular carcinoma
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85016618569&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/57864
_version_ 1681424958062854144